Literature DB >> 8050139

Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days.

J Faergemann1, H Zehender, L Millerioux.   

Abstract

In earlier skin pharmacokinetic studies we have shown that terbinafine is rapidly delivered to the stratum corneum, nails and hair both through sebum and by direct diffusion through dermis-epidermis. In the present study the skin pharmacokinetic profile of terbinafine was studied in two groups of eight human male volunteers during and after 250 mg orally once daily for 7 and 14 days. In the 7-day study high terbinafine levels were found in sebum (19.0 micrograms/g) and stratum corneum (2.5 micrograms/g), and a concentration in stratum corneum above the minimal inhibitory concentration for most dermatophytes was still found 48 days after the last day of medication. Terbinafine was found in peripheral nail clippings after 7 days of medication and the concentration was, in the 7-day study, 0.5 microgram/g 1 day after stopping medication; it was still 0.2 microgram/g 90 days after stopping treatment. The results in the 14-day study were in parallel with, but higher than, in the 7-day study. The elimination of terbinafine from several compartments is biphasic, with a faster initial elimination followed by a slower secondary elimination. For nails, the elimination is slower compared with the other compartments. The results indicate that terbinafine may be effective in short-term treatment of several dermatophytoses. The concentration of 0.2 microgram/g of terbinafine found in nails 90 days after stopping medication, following 7 days of treatment, indicates that the duration of therapy, even in tinea ungium, may be shorter than is currently the case.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8050139     DOI: 10.1111/j.1365-2230.1994.tb01138.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  15 in total

Review 1.  Drugs in nails: physiology, pharmacokinetics and forensic toxicology.

Authors:  A Palmeri; S Pichini; R Pacifici; P Zuccaro; A Lopez
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 2.  Onychomycosis. Going for cure.

Authors:  A K Gupta; N H Shear
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

Review 3.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 4.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Onychomycosis. New therapies for an old disease.

Authors:  A K Gupta; R K Scher; P De Doncker; D N Sauder; N H Shear
Journal:  West J Med       Date:  1996-12

6.  Correlation of In Vitro Susceptibility Based on MICs and Squalene Epoxidase Mutations with Clinical Response to Terbinafine in Patients with Tinea Corporis/Cruris.

Authors:  Ananta Khurana; Aradhana Masih; Anuradha Chowdhary; Kabir Sardana; Sagar Borker; Aastha Gupta; R K Gautam; P K Sharma; Dhruv Jain
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

7.  Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group.

Authors:  M Bräutigam; S Nolting; R E Schopf; G Weidinger
Journal:  BMJ       Date:  1995-10-07

8.  [Onychomycosis].

Authors:  D Reinel
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

9.  Physiologically based pharmacokinetic model for terbinafine in rats and humans.

Authors:  Mahboubeh Hosseini-Yeganeh; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

10.  Intermittent pulse-dosed terbinafine in the treatment of tinea corporis and/or tinea cruris.

Authors:  V Shivakumar; Rajendra Okade; V Rajkumar; K Sajitha; S R Prasad
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.